We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Agilent, Invitrogen End Lengthy Patent Battle

Law360 (February 6, 2008, 12:00 AM EST) -- Measurement company Agilent Technologies has settled with Invitrogen Corp. in three long-running patent infringement suits over genetic technology between Invitrogen and Stratagene Corp., which Agilent took over last year.

Santa Clara, Calif.-based Agilent will pay an undisclosed sum to Invitrogen and all litigation will be dismissed, according to a joint statement the companies issued Tuesday.

In addition, Agilent has agreed to stop selling its RNase H minus reverse transcriptase products, and Invitrogen will get a license from Agilent and pay a confidential royalty fee to sell...
To view the full article, register now.